Trial reportFrontiers in nutrition2026
Effects of aged black garlic (ABG10+
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04915053 (Black Garlic Nutraceuticals Supplementation for the Control of Blood Pressure in Hypertension. A Triple-blind Randomized Placebo Control Study.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Black Garlic Nutraceuticals Supplementation for the Control of Blood Pressure in Hypertension. A Triple-blind Randomized Placebo Control Study.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aged black garlic (ABG) is rich in organosulfur compounds such as S-allyl-cysteine (SAC) and may influence lipid metabolism, although evidence from controlled trials remains limited. The aim of this study was to evaluate the impact of a low-dose SAC-optimized ABG on blood lipid profiles in Grade I hypertensive individuals. Methods: A randomized, triple-blind, placebo-controlled trial with systematic sex-stratified sequential allocation was conducted with 75 Grade I hypertensive participants receiving either 250 mg of ABG or a placebo daily for 12 weeks. Plasma lipoproteins and subclass composition were quantified by NMR spectroscopy, and metabolic clusters were explored using k-means and PLS-DA. Results: ABG supplementation did not produce statistically significant changes in any conventional lipid marker (total cholesterol, LDL-C, HDL-C, or triglycerides). In secondary exploratory analyses of NMR-derived lipoprotein subclasses, nominally significant differences were observed: ABG was associated with a reduction in the total number of particles and HDL particles. Detailed analysis of XXL-VLDL particles showed a decrease in the percentage of free and esterified cholesterol alongside an increase in triglyceride percentage. Large HDL particles showed compositional remodeling characterized by an increase in phospholipid content and a decrease in triglyceride percentage. In exploratory cluster analyses, participants with a more adverse baseline metabolic profile showed a nominally significant reduction in total triglycerides and VLDL-lipid content after ABG intake. Conclusion: Low-dose ABG supplementation did not significantly modify conventional lipid markers in Grade I hypertensive individuals. However, secondary exploratory NMR-based analyses suggest that ABG may induce compositional remodeling of lipoprotein subclasses-particularly reducing the cholesterol load in large VLDL particles and enhancing HDL phospholipid content-especially in individuals with a more adverse baseline metabolic profile. These findings are hypothesis-generating and require confirmation in adequately powered trials with pre-specified NMR endpoints. Clinical Trial Registration: identifier: NCT04915053.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.